Oral Oxbryta Safe, Effective Over Long Term and in Real World

Oral Oxbryta Safe, Effective Over Long Term and in Real World

313054

Oral Oxbryta Safe, Effective Over Long Term and in Real World

Long-term treatment with Oxbryta (voxelotor) safely and effectively reduced anemia and red blood cell destruction (hemolysis), while keeping a low rate of painful vaso-occlusive crises (VOCs), in adolescents and adults with sickle cell disease (SCD). That’s according to nearly three years of data from the Phase 3 HOPE trial and its extension study. These findings, along with real-world data consistent with those of HOPE (NCT03036813), will be presented by Global Blood Therapeutics (GBT), the therapy’s…

You must be logged in to read/download the full post.